Curriculum Vitae

Curriculum Vitae
Persönliche Daten:
Name:
Geburtsdatum:
Geburtsort:
Staatsangehörigkeit:
Familienstand:
Privatadresse:
Tel:
Email:
Dr. rer. nat. Thomas Henkel
11. 11. 1963
Kassel, Hessen
deutsch
verheiratet mit Helen G. Stachelek, 1 Sohn, geb. 1998
Rudolfstr. 2, 82166 Gräfelfing
089-89545763
[email protected]
Geschäftsadresse:
Telefon:
Fax:
Targos Molecular Pathology Gmbh,
Germaniastr. 7, 34119 Kassel
0561-50045300
0561-50045352
Büro München:
089-21112221
089-21112220
Email:
[email protected]
Telefon:
Fax:
Akademische Ausbildung:
1990 - 1993
Ludwig-Maximilians Universität München
Abschluß: Dr. rer. nat in Chemie (Biochemie)
("summa cum laude")
1982 - 1989
Georg-August Universität Göttingen
Abschluß: Diplom in Biologie
("sehr gut")
1973 - 1982
Heinrich-Schütz-Schule Kassel
Abschluß: Abitur
("sehr gut")
Berufserfahrung:
2014 – heute
Director of the Board, Targos Inc., USA
2010 – heute
Vorstand Targos Advance AG
2010 – heute
Vorstand Targos Development AG
2005 – heute
Gesellschafter und Geschäftsführer
Targos Molecular Pathology GmbH, Kassel
2004 - heute
Lehrauftrag für Biochemie, Universität Kassel
2002 - 2010
Consultant, Procyon Biomedical Consulting
2002 - 2005
Leiter Biomedizinische Forschung, Klinikum Kassel GmbH, Kassel
2000 - 2002
Forschungsleiter, MediGene AG, Martinsried
1999 - 2000
Hauptabteilungsleiter „Forschung“, MediGene AG, Martinsried.
1995 - 1999
Abteilungsleiter „Molecular Cardiology“, MediGene AG, Martinsried.
1993 - 1995
Postdoktorat, Biology Department, Tularik Inc.
South San Francisco, CA, USA.,
Direktor: Dr. S. L. McKnight
1990 - 1993
Doktorat, Genzentrum der Ludwig-Maximilians Universität,
Martinsried, Direktor: Prof. Dr. Ernst-Ludwig Winnacker
Thema: Der induzierbare Transkriptionsfaktor NF-κB:
Studien zur Kontrolle des Kerntransportes und zum
Mechanismus der Aktivierung.
Jan. - March 1992
Gastwissenschaftler, Hadassah Medical School,
The Lautenberg Center of Tumor Immunology, Jerusalem, Israel
Gastgeber: Dr. Yinon Ben-Neriah
Feb. 1991
Gastwissenschaftler, Salk Institute, Molecular Biology and
Virology Laboratory, San Diego, CA, USA.
Gastgeber: Prof. Dr. Inder Verma
Jan. - March 1990
Forschungsassistent, Boehringer Mannheim, Abt. Genetik,
Penzberg.
Supervisor: Dr. Helmut Burtscher
1988 - 1989
Diplomand, MPI für experimentelle Medizin,
Abt. Immunchemie, Göttingen
Direktor: Prof. Dr. Norbert. Hilschmann
Diplomarbeit: Überprüfung der Identität eines cDNA-Klones
aus der Leukämiezellinie KM3.
1986 - 1987
Forschungsassistent, Max-Planck-Institut für experimentelle Medizin,
Abt. Immunchemie, Göttingen
Supervisor: Dr. Shitsu Barnikol-Watanabe
Stipendien:
1995
1994 - 1995
1990 - 1993
Stipendiat des DKFZ („AIDS-Stipendium“)
Stipendium der Deutschen Forschungsgemeinschaft
Stipendiat des Boehringer Ingelheim Fonds
Fortbildung:
2002
2002
2001
2001
2000
1999
Management Kurs: Führung & Konflikte
Management Kurs: Qualitätsmanagement
Management Kurs: Kommunikation
Management Kurs: Projektmanagement
Seminar: Patente in der Biotechnologie
Management Kurs: „Führung von Forschung & Entwicklung“
Management Center St. Gallen (CH)
Mitgliedschaften:
2003 - 2005
Editorial Board von Targets, Elsevier Publishing
2002
Vorstand Sektion Biotechnologie der DECHEMA e.V.
2002 - 2004
Wissenschaftlicher Beirat, MediGene AG
Sprachen:
deutsch, englisch, portugiesisch
Veröffentlichungen:
Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O. ErbB2 diagnostics in breast
cancer--an update. Pathologe. 2009 Mar;30(2):147-55.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J,
Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a
validation study. Histopathology. 2008 Jun;52(7):797-805.
Stoss O, Werther M, Zielinski D, Middel P, Jost N, Ruschoff J, Henkel T, Albers P.
Transcriptional profiling of transurethral resection samples provides insight into
molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer
Prostatic Dis. 2008;11(2):166-72; Epub 2007 Jul 24.
Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M,
Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab
(Herceptin(R)) Phase II monotherapy study: assessment of test sensitivity and impact of
chromosome 17 polysomy., J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.
Stoss O, Jost N, Czeloth K, Ruschoff J, Henkel T, Albers P. Urologe A. 2007
Sep;46(9):1117-9.
Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J.
Her-2/neu analysis--new data? Verh Dtsch Ges Pathol. 2006; 90:107-13.
Roessler M., Rollinger W., Mantovani-Endl L., Hagmann M._L., Palme S., Berndt P.,
Engel A., Pfeffer M, Karl J, Bodenmueller H, Rüschoff J, Henkel T, Rohr G., Rossol S.,
Rösch W., Langen H., Zolg W, and Tacke M (2006) Identification of PSME3 as a novel
serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide
gel electrophoresis with a strictly mass spectrometry-based approach for data analysis
Mol. Cell. Proteomics August 6, 2006, 10.1074/mcp.M600118-MCP200
Roessler, M., Rollinger, W., Palme, S., Hagmann, ML., Berndt, P., Engel, AM.,
Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J.,
Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M. (2005)
Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for
Colorectal Cancer. Clin Cancer Res. 2005 Sep 15;11(18):6550-6557.
Stoss, O. and Henkel T. (2004) Biomedical marker molecules for cancer – current status
and perspectives. Drug Discovery Today Targets, 3(6), 228-237
Schmidtgen, C. and Henkel T. (2004) Gewebebanken in der Biomedizinischen Forschung.
BioForum 1/04
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and
Henkel, T. (2003) Emerging molecular targets for chronic heart failure (Part II). Exp.
Opinion Therap.Targets 7(1):pp
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and
Henkel, T. (2002) Emerging molecular targets for chronic heart failure (Part I). Exp.Opinion
Therap.Targets 6(6):649-658
Stoss, O., Reuner, B. and Henkel, T. (2002) RNA Expression profiling in cardiac tissue
– a successful route to new drug targets? Targets 1, 12-19
Nave, B.T., Becker, M., Roenicke, V., Henkel, T. (2002) Validation of targets and drug
candidates in an engineered three-dimensional cardiac tissue model.
Drug Discov Today Apr 1;7(7):419-425
Funk, M., Niedenthal, R., Mumberg, D., Brinkmann, K., Rönicke, V. and Henkel, T. (2002)
Vectors systems for the heterologous expression of proteins in Saccharomyces cerevisiae.
In Guide to Yeast Genetics and Molecular Cell Biology Part B, Methods in Enzymology,
Vol 350: 248
Henkel, T. (1999) Therapeutic Innovation. IDrugs 2(5):403-404
Henkel, T. & Klein, H.-G. (1998) Differentielle Genexpression. Medizinische Genetik 2:356
Hsieh, J.J.D, Henkel, T., Salmon, P., Robey, E., Peterson, M.G. and Hayward, S.D. (1996)
Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism
resembling that of Epstein-Barr Virus EBNA-2. Mol. Cell. Biol. 16, 952-959
Traenckner, E.B.M, Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S. and Baeuerle, P.A.
(1995) Phosphorylation of human IκB- on serines 32 and 36 controls IκB-α proteolysis
and NF-κB activation in response to diverse stimuli. EMBO J. 14, 2876-2883
Henkel, T., Ling, P.D., Hayward, S.D. and Peterson, M.G. (1994) Mediation of Epstein-Barr
Virus EBNA2 trans-activation by Recombination Signal-Binding Protein Jκ. Science, 265,
92 - 95.
Baeuerle, P.A. and Henkel, T. (1994) Function and activation of NF-κB in the immune
system. Annu. Rev. Immunol. 12, 141-179.
Groß, N. A., Henkel, T., Karabinos, A., Götz, H., Barnikol-Watanabe, S. and Hilschmann,
N. (1994) Human protein NEFA, a novel DNA binding/EF-hand/ leucine zipper protein -
Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the
protein. Biol. Chem. Hoppe Seyler, 375, 497-512
Machleidt, T., Wiegmann, K., Henkel, T., Schütze, S., Baeuerle, P. and Krönke, M.
(1994), Sphingomyelinase activates proteolytic IκB-a degradation in a cell-free system.
J. Biol. Chem. 269, 13760-13765
Henkel, T., Machleidt, T., Alkalay I., Krönke M., Ben-Neriah, Y. and P.A. Baeuerle
(1993) Rapid proteolysis of IκB- is necessary for activation of transcription factor NF-κB.
Nature 365, 182-185
Zabel, U., Henkel, T., dos Santos Silva, M. and Baeuerle, P.A. (1993) Nuclear uptake
control of NF-κB by MAD-3, an IκB protein present in the nucleus. EMBO J. 12, 201-211
Henkel, T., Schmitz, M.L. and Baeuerle, P.A. (1993) Rapid characterization of lambda
cDNA clones after amplification and radioactive labeling with the PCR technique.
BioTechniques, 14 (6), 3 - 4
Henkel, T and P.A. Baeuerle (1993) Functional analysis of mutated cDNA clones by direct
use of PCR products in in vitro transcription/translation reactions. Anal. Biochem. 214,
351-352
Henkel, T., Zabel, U., van Zee, K., Müller, J., Fanning, E. and Baeuerle, P.A. (1992)
Intramolecular masking of the nuclear location signal and dimerization domain in the
precursor of the p50 NF-κB subunit. Cell 68, 1121-1133
Ruben, S., Dillon, P.J., Schreck, R., Henkel, T., Chen, C.-H., Maher, M., Baeuerle, P.A.
and Rosen C. (1991). Isolation of a rel- related human cDNA that potentially encodes the
65-kD subunit of NF-κB Science 251: 1490-1493
Patente:
16 Patentanmeldungen, 4 Patente erteilt:
Method for identifying substances directed against myocardial cell hypertrophy
PCT/WO 02/097128A2 published 05.12. 2002
Inventors: T. Henkel, V. Rönicke, B. Navé
Applicant: MediGene AG
Herz- und Skelettmuskelspezifische Nukleinsäure, ihre Herstellung und Verwendung.
German Patent issued 15.6. 2000
Inventors: T. Henkel, M. Hofmann & H. Domdey
Applicant: MediGene AG
Novel synthetic protein structural templates for the generation, screening and evolution of
functional molecular surfaces
PCT/EP97/02840 filed 30.05 1997
Inventors: B. Steipe, H. Bruhn, M. Funk, T. Henkel
Applicant: MediGene AG
Epstein-Barr virus transcription factor binding assay
US Patent 5,679,525 issued 21.10. 1997
Inventors: T. Henkel & M. G. Peterson
Applicant: Tularik Inc.
Process for inhibiting the transcription of genes
US Patent 6,090,542 issued 18.7. 2000
Inventors: T. Henkel & P.A. Bäuerle
Applicant: Boehringer Ingelheim International GmbH et al.